Repligen Grows Revenue 48% in Q2
Drug pipelines are so overrated. Over the last decade, Repligen (NASDAQ: RGEN) has quietly crushed its niche of selling the equipment needed to safely and efficiently manufacture biologic drugs. That much is evident from the stock's 10-year return of 1,680%, and the latest operating results for the second quarter of 2019.
The business reported record quarterly revenue, which is nothing new considering the pace of sales growth. Repligen delivered year-over-year revenue growth of 48% in Q2 and more than doubled operating income in the first half of 2019, compared with the year-ago period. That gave management the confidence to once again raise full-year 2019 guidance for revenue, although it will come at the expense of slightly lower earnings as an important acquisition is integrated. Here's what investors need to know about the latest operating results.
The latest acquisition could make sampling larger bioreactors a breeze, unlike this scientist's experience. Image source: Getty Images.
Quelle Fool.com
